LFM-A13 - CAS 244240-24-2
Catalog number:
244240-24-2
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C11H8Br2N2O2  
Molecular Weight:
360
COA:
Inquire
Targets:
Polo-like Kinase (PLK)
Description:
LFM-A13 is a specific Bruton's tyrosine kinase (BTK) with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and IRK.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
N/A
MSDS:
Inquire
1.Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Robak T1, Robak E. Expert Opin Investig Drugs. 2012 Jul;21(7):921-47. doi: 10.1517/13543784.2012.685650. Epub 2012 May 22.
INTRODUCTION: In the last few years, several tyrosine kinase inhibitors (TKIs) have been synthesized and become available for preclinical studies and clinical trials. This article summarizes recent achievements in the mechanism of action, pharmacological properties, and clinical activity and toxicity, as well as the emerging role of TKIs in lymphoid malignancies, allergic diseases, and autoimmune disorders.
2.[Role of non-receptor tyrosine kinase Tec in the production of pro-inflammatory cytokines from macrophages induced by endotoxin/lipopolysaccharide].
Wang C1, Wang F1, Zhou B1, Qiu L1, Wang J1, Liu S1, Chen X2. Zhonghua Shao Shang Za Zhi. 2015 Feb;31(1):11-5.
OBJECTIVE: To investigate the role of non-receptor tyrosine kinase Tec in the production of TNF-α and IL-1β from macrophages induced by LPS and its related mechanism.
3.Ibrutinib and novel BTK inhibitors in clinical development.
Akinleye A1, Chen Y, Mukhi N, Song Y, Liu D. J Hematol Oncol. 2013 Aug 19;6:59. doi: 10.1186/1756-8722-6-59.
Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders. Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical effectiveness and tolerability in early clinical trials and has progressed into phase III trials. However, additional research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition. This review summarizes preclinical and clinical development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292, and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.
4.Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.
Aalipour A1, Advani RH. Br J Haematol. 2013 Nov;163(4):436-43. doi: 10.1111/bjh.12573. Epub 2013 Sep 24.
Constitutive or aberrant signalling of the B cell receptor signalling cascade has been implicated in the propagation and maintenance of a variety of B cell malignancies. Small molecule inhibitors of Bruton tyrosine kinase (BTK), a protein early in this cascade and specifically expressed in B cells, have emerged as a new class of targeted agents. There are several BTK inhibitors, including ONO-WG-307, LFM-A13, dasatinib, CC-292, and PCI-32765 (ibrutinib), in preclinical and/or clinical development of which ibrutinib is currently in phase III trials. Recent clinical data suggest significant activity of ibrutinib as a first in class oral inhibitor of BTK. This review provides an overview of ongoing clinical studies of BTK inhibitors.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Polo-like Kinase (PLK) Products


CAS 592542-60-4 Rigosertib sodium

Rigosertib sodium
(CAS: 592542-60-4)

Rigosertib, a synthetic benzyl styryl sulfone, is a non-ATP-competitive inhibitor of PLK1 (IC50=9 nM).

CAS 1228960-69-7 MLN0905

MLN0905
(CAS: 1228960-69-7)

MLN0905 is a potent, selective small-molecule PLK1 inhibitor. MLN0905 inhibits cell proliferation in a broad range of human tumor cells including DLBCL cell lin...

CAS 244240-24-2 LFM-A13

LFM-A13
(CAS: 244240-24-2)

LFM-A13 is a specific Bruton's tyrosine kinase (BTK) with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and I...

CAS 592542-59-1 Rigosertib

Rigosertib
(CAS: 592542-59-1)

Rigosertib, a synthetic benzyl styryl sulfone, is a non-ATP-competitive inhibitor of PLK1 (IC50=9 nM).

CAS 321688-88-4 Poloxin

Poloxin
(CAS: 321688-88-4)

Poloxin is the first small-molecule inhibitor specifically targeting the function of the Plk1 PBD. Poloxin induces centrosome fragmentation and abnormal spindle...

CAS 1062243-51-9 Ro5203280

Ro5203280
(CAS: 1062243-51-9)

Ro5203280 is a small-molecular PLK1 inhibitor. Ro5203280 shows a high efficacy for suppressing nasopharyngeal carcinoma growth with low toxicity in mouse studie...

CAS 755038-65-4 Volasertib

Volasertib
(CAS: 755038-65-4)

BI 6727 (Volasertib) is a small highly potent Polo-like kinase inhibitor (Plk) with an IC50 of 0 .87 nM and EC50 of 11-37 nM on a panel of cancer cell lines, w...

TAK-960 hydrochloride
(CAS: 1137868-96-2)

The hydrochloride salt form of TAK-960, a newly studied selective PLK1 inhibitor, might have potential effect in inhibiting proliferation of sorts of cancer cel...

CAS 131247-39-8 ON1231320

ON1231320
(CAS: 131247-39-8)

ON1231320, also known as GBO-006, was found to be a specific Polo like kinase 2 (PLK2) inhibitor when profiled against a panel of 288 wild-type, 55 mutant and 1...

CFI-400945
(CAS: 1338806-76-0)

CFI-400945, has been found to be a PLK4 inhibitor that could be probably useful in anticancer studies through influencing mitosis and inducing apoptosis. It is ...

CAS 1137868-52-0 TAK-960

TAK-960
(CAS: 1137868-52-0)

TAK-960 is an orally available PLK1 inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor TAK-960 selectively inhibits PLK1, inducing ...

CAS 1052532-15-6 SBE-13 HCl

SBE-13 HCl
(CAS: 1052532-15-6)

SBE13 is a cell-permeable highly potent polo-like kinase (Plk1) inhibitor that targets the inactive conformation of the kinase. SBE13 does not effect the activi...

CAS 929095-18-1 GSK-461364

GSK-461364
(CAS: 929095-18-1)

GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kin...

CFI-400945 Fumarate
(CAS: 1616420-30-4)

The fumarate salt form of CFI-400945, has been found to be a PLK4 inhibitor that could be probably useful in anticancer studies through influencing mitosis and ...

CAS 173529-46-9 HMN-214

HMN-214
(CAS: 173529-46-9)

HMN-214 is an oral prodrug of HMN-176, a stilbene derivative that interferes with the subcellular spatial location of polo-like kinase-1, a serine/threonine kin...

TAK-960 dihydrochloride

TAK-960 is an orally available, potent and selective PLK1 inhibitor that was in a phase I clinical trial in patients with advanced non-hematologic malignancies.

CAS 1034616-18-6 NMS-1286937

NMS-1286937
(CAS: 1034616-18-6)

NMS1286937, also know as NMS-P937, is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-l...

CAS 660868-91-7 GW843682X

GW843682X
(CAS: 660868-91-7)

GW843682X is a cell-permeable thiophene-benzimidazole compound that acts a selective PLK1 and PLK3 inhibitor with IC50s of 2.2 nM(PLK1) and 9.1 nM(PLK3).

SBE13
(CAS: 775294-82-1)

SBE13 is a cell-permeable highly potent polo-like kinase (Plk1) inhibitor that targets the inactive conformation of the kinase. Its IC50 value is 0.2 nM. It doe...

Chemical Structure

CAS 244240-24-2 LFM-A13

Quick Inquiry

Verification code

Featured Items